Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-ORB: Alpelisib or Buparlisib + Letrozole in Neoadjuvant Breast Cancer
NCT01923168Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2014
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial of alpelisib in Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative) (3 arms), sponsored by Novartis. Primary endpoints: Pathological Complete Response (pCR) in PIK3CA Mutant Cohort at 24 weeks, Pathological Complete Response (pCR) in PIK3CA Wild-type Cohort at 24 weeks and 2 more. Started Mar 2014; status: completed.
02
Drugs
alpelisib
03
Conditions
Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative)
Beyond the preview
Go deeper on NCT01923168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01923168.